Folosim cookie-uri pentru a îmbunătăți experiența pe site. Pentru detalii, citește Politica de confidențialitate.

Small risk of severe acute pancreatitis with weight-loss jabs, MHRA says

29.01.2026 21:23 | The Guardian World

Agency updates guidance after increase in reports of condition to the yellow card schemePatients on weight-loss jabs should be aware there is a small risk of developing severe acute pancreatitis, the medicines regulator has said.About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight, according to recent research. Continue reading...

🔗 Citește articolul complet pe The Guardian World